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Introduction
Obesity (body mass index [BMI] > 30 kg/m²) has been recognised 
as a chronic disease by the World Health Organization (WHO). It is 
characterised by alterations in metabolic function, which result in an 
increase in total body fat mass as well as an accumulation of visceral 
adipose tissue.1 In the modern era, excess energy is available to fuel 
obesity because of a general decrease in energy expenditure and an 
overall increase in calorie intake. 
The rise of obesity is exponential and has been described as 
an epidemic within an epidemic.2 Between 1986 and 2000 the 
prevalence of obesity (BMI ≥ 30 kg/m2) doubled, morbid obesity (BMI 
≥ 40 kg/m2) quadrupled and super obesity (BMI ≥ 50 kg/m2) increased 
five-fold in adults in the USA.2 Even more alarming is the fact that a 
similar increase is being observed in the paediatric population.2 The 
morbidly obese population is characterised by an average decrease 
in life expectancy of nine years in females and twelve years in males.2 
The prevalence of obesity is increasing in most African countries, 
particularly in individuals living in urban areas.
Although obesity is strictly dependent on an excess of energy intake 
over energy expenditure, a large body of research has illustrated the 
importance of the genetic susceptibility of certain individuals in the 
generation of this imbalance. Thus, obesity can be described as a 
multi-factorial disease, meaning that both genetic and environmental 
factors contribute to its development, as well as to the expression of 
its co-morbidities.3 The focus of this review is to address obesity from 
a basic science perspective, with specific reference to monogenic 
abnormalities that appear to be associated with the disease.
Obesity in South Africa
Obesity is seen in both developed and developing countries and 
South Africa is one of several developing countries in which obesity is 
becoming increasingly prevalent.4 It is not unusual to see individuals 
who are underweight and obese in the same household. Another 
striking feature is the correlation, in the same individual, between 
low birth weight and the appearance of features of the metabolic 
syndrome later in life.4 According to the guidelines of the International 
Diabetes Federation (IDF), these include the following: abdominal 
obesity (based on race-specified values for waist circumference), a 
fasting plasma glucose of ≥ 5.6 mmol/L or previously diagnosed type 
2 diabetes, elevated blood pressure (systolic ≥ 130 mmHg or diastolic 
≥ 85 mmHg or treatment of previously diagnosed hypertension), 
dyslipidaemia (plasma triglycerides > 1.7 mmol/L; HDL cholesterol: 
men < 1.03 mmol/L; women < 1.29 mmol/L or treatment for any of 
these two lipid abnormalities).
In South Africa, the prevalence of combined overweight (BMI 25– 
30 kg/m2) and obesity (BMI > 30 kg/m2) has reached alarming 
levels in the economically active adult population (18 to 65 years). 
In a random sample of 13 089 South African individuals, mean 
BMI figures were 22.9 kg/m2 and 27.1 kg/m2 for men and women 
respectively.5 A total of 29.2% of the men and 56.6% of the women 
were overweight or obese (BMI ≥ 25 kg/m2). Abdominal obesity was 
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found in 9.2% of the men and 42% of the women.5 Table I shows the 
percentage of South African adults with a BMI > 25 kg/m2 according 
to population groups: 
Urbanisation is a major contributor to the high prevalence of obesity 
seen in South African communities.5 With regard to patterns of 
nutritional status and food intake, there appears to be a correlation 
between urbanisation and lack of concern for dietary composition 
and intake.5 With regard to dietary intake, the adult South African 
population (age ≥ 15 yrs) is characterised by overnutrition, due 
largely to an increase in calorie intake in the form of total fat.5 
Abdominal obesity and overweight are therefore highly prevalent in 
adult South Africans, specifically in black African women and white 
men.5 Education in general, and the challenging of certain cultural 
perspectives with regard to obesity, are necessary steps in the 
management of the South African obesity epidemic.5
The melanocortin 4 receptor (MC4R)
The Melanocortin 4 Receptor (MC4R) is expressed in a number of 
locations in the central nervous system, and is concentrated in the 
paraventricular nucleus of the hypothalamus.7 The MC4R is a member 
of the A super-family of G protein-coupled receptors.8 It is encoded 
by a gene that contains a single exon and is located on chromosome 
18q22.9 It consists of a single 332 amino acid polypeptide chain that 
contains seven α-helical transmembrane domains, an extracellular 
N-terminus, three extracellular loops, three intracellular loops and an 
intracellular C-terminus (Figure 1).10
The MC4R is involved mainly in energy homeostasis, but also in 
sexual function, particularly erectile function.11 Its primary function 
is to regulate food intake following the binding of α-melanocyte-
stimulating hormone (α-MSH), which provides an anorexigenic/
satiety signal through the activation of the cyclic adenosine 
monophosphate (cAMP) second messenger system.9
Polymorphisms in MC4R and their phenotypic 
classification
Individuals who carry mutations in the MC4R gene are not 
characterised by impairment in energy expenditure. Obesity in 
these individuals is due to a hyperphagic state.12 The phenotype 
includes an increase in fat mass, linear growth and lean mass, 
extensive hyperinsulinaemia,13 an increase in bone mineral density,14 
hyperphagia in early childhood and possibly binge-eating disorder.15 
These individuals also present with an elevated prevalence of the 
metabolic syndrome, which includes an increase in abdominal 
obesity, glucose intolerance, dyslipidaemia and hypertension.16
The extent of the differences in eating behaviour between carriers 
of pathogenic MC4R polymorphisms and non-carriers has not 
been observed in individuals with mutations in other genes that 
are involved in the leptin/melanocortin pathway, for example pro-
opiomelanocortin (POMC) and the leptin receptor. This points to the 
importance of MC4R polymorphisms in affecting eating behaviour.16 
This was confirmed by Farooqi and colleagues, who found that the 
severity of the functional defect of the receptor correlated positively 
with food intake at a test meal.17
Male and female adult subjects harbouring pathogenic MC4R 
mutations have an elevated risk of obesity; the quantification of this 
observation in relation to BMI has revealed an increase of ~4 and 
~9.5 kg/m2 respectively when compared to wild-type relatives.18 
According to Lubrano-Berthelier and colleagues, a specific MC4R 
mutation carrier phenotype has not been identified and therefore the 
prediction of an MC4R mutation cannot be made based on phenotypic 
(clinical) observation alone.19 However, these authors confirm that 
MC4R mutations are a significant cause of severe human obesity in 
both early and late onset forms of the disease.  
Functional impact of MC4R mutations
A correlation between the severity and onset of obesity and the degree 
of MC4R dysfunction has been clearly defined. Functional defects in 
the MC4 receptor that are responsible for obesity include decreased 
or absent ligand binding, decreased cell surface receptor expression 
(due to intracellular receptor retention), incorrect protein folding 
(which prevents the release of the receptor from the endoplasmic 
reticulum20) and a reduction in signal transduction.9 Of these 
functional defects, those that cause intracellular receptor retention 
result in the most severe forms of obesity,19 and are proposed to be 
the best predictors of the onset and severity of obesity in carriers of 
pathogenic MC4R mutations.
The most common functional receptor defect found in individuals 
with pathogenic MC4R mutations is a reduction in the constitutive 
activity of the receptor.9 Normal constitutive receptor activity results 
in basal cAMP generation in the absence of an agonist.12 N-terminal 
sequences are responsible for the constitutive activity which is 
compromised if mutations arise within this domain.12 Mutations of 
Table I: Percentage of South African adults with a BMI > 25 kg/m2 
Ethnic group Female Male Ref
Black 57.2 27.1 5
 74.6 49.3 6
Mixed race 52.4 31.2 5
66.0 45.7 6
Asian 48.0 32.7 5
37.0 35.5 6
White 50.8 56.1 5
42.2 56.4 6









Figure 1: The structure of MC4R showing the seven α-helical transmembrane 
domains, the three extracellular and three intracellular loops, the extracellular 
N-terminus, the intracellular C-terminus and the coupling of the receptor to a 
heterotrimeric G-protein.
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this nature have only been identified in obese individuals, which 
implies that a loss of or decline in basal MC4R is likely to affect the 
regulation of body weight.12 In 2008, a total of 100 mutations in the 
MC4R gene were described,8 30% of which comprised frameshift or 
nonsense mutations and 70% of which were missense mutations 
that impaired signalling through cyclic AMP in vitro.8
The identification of a mutation/polymorphism in the MC4R gene 
does not necessarily imply that it is involved in the pathogenesis 
of the disease. In vitro functional confirmation is required to 
demonstrate that a mutation is pathogenic.21 Thus there are many 
MC4R polymorphisms that occur commonly in both obese and non-
obese individuals that have no consequence for the function of the 
receptor and are referred to as non-pathogenic.19 This highlights 
the importance of functional studies, especially when investigating 
the therapeutic potential of mutant receptors. It should be pointed 
out, however, that there are exceptions to this rule: normal receptor 
function has been observed in obese individuals and, conversely, 
loss-of-function mutations have been seen in the non-obese.21
MC4R mutational prevalence and inheritance 
mechanisms
Obesity is most commonly considered to be a polygenic disease. 
However, monogenic forms of obesity do exist, and the affected 
genes described thus far include leptin, the leptin receptor, POMC, 
pro-hormone convertase-1 and MC4R.3 Forty to seventy percent 
of an individual’s body weight is genetically determined, with the 
remaining contribution coming from the quality and quantity of food 
that is consumed.20 An investigation of monogenic obesity disorders, 
despite their rarity, is an important step in the destigmatisation of 
the disease, i.e. in highlighting the fact that there is an undisputed 
biological basis for its development.8
MC4R deficiency is one of the most common human monogenic 
disorders.22 MC4R mutations have a population prevalence of at least 
1 in 2 000 (0.05%),22,23 are found in 0.5% to 1% of obese adults22,23 
and are accountable for 6% of all severe cases of the disease 
starting in childhood.10,22-24 With regard to penetrance, carriers of 
MC4R mutations will pass these on to their offspring with an 82% 
frequency, and individuals that carry mutations that affect function 
have a 4.5-fold increased risk of developing obesity as opposed to 
non-carriers.12 The accepted mode of inheritance of MC4R mutations 
is co-dominance with modulation of penetrance and expressivity.8 
This inheritance pattern explains why homozygous carriers are more 
obese than heterozygous carriers.25 Finally, the frequency of MC4R 
mutations is dependent on the ethnicity of the study group.12 
Two factors have thus been proposed to explain discrepancies in 
MC4R mutation phenotypic penetrance. First, ethnic background, 
and second, whether or not the mutation leads to a receptor-function 
defect.25 Both of these factors impact on the severity of the phenotype, 
which is more extreme in those individuals that have complete loss 
of receptor function: individuals that harbour mutations that totally 
abolish MC4R function have a higher BMI than those that have 
mutations that retain partial receptor function.26 A decrease in the 
amount of functional MC4R also has a direct causative effect on the 
control of body weight.17 Consequently, persons that are homozygous 
carriers have a higher BMI than those that are heterozygous carriers 
for the same mutation.26 The transmission of mutations leading 
to either loss of function or reduced function occurred at a rate 
of 81.8%. In addition, all mutations were transmitted to offspring 
in favour of the wild-type alleles.12 Arguments for an autosomal 
dominant segregation pattern have also been proposed.12 It would 
seem, however, that this theory is questionable, as the observed 
phenotypes do not confirm its assumptions. 
Concluding remarks
Obesity has become a major health care problem in the last few 
decades and is an important contributor to the increasing rate 
of global mortality. Bariatric surgical treatment has consistently 
been shown to be a very effective means of achieving weight loss 
and to be effective in the resolution of co-morbidities. Identifying 
genetic mechanisms that contribute to the development of the 
disease and using them to implement therapeutic strategies at both 
pharmacological and surgical levels is likely to become important 
in the future. In cases of monogenic obesity, for example, the most 
effective form of management would be bariatric surgery at an earlier 
age, rather than the more conservative approaches to treatment. The 
genetically-induced malfunction of proteins such as MC4R, which 
are involved in appetite regulation and energy homeostasis, could 
be used as markers in diagnostic strategies, and as predictors for 
therapeutic outcome in obesity management once the pathogenesis 
has been confirmed. 
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